Center on Health Equity & Access

Esketamine's monotherapy approval and new real-world data are forcing a reckoning for managed care.

A clinical pharmacy leader outlines 8 interdependent domains institutions must master to build financially sustainable, patient-accessible CGT programs.

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia.

The global prevalence of MASLD was 16.1% as recently as 2023, with many individuals being asymptomatic and carrying a major risk of future complications.

Equity gaps in lung cancer molecular testing persist; reflex testing and nurse navigation speed care, while coverage and access barriers stall outcomes

Housing and transportation barriers were linked to lower CRC screening rates, especially among adults aged 50 to 64.

Reflex molecular testing and nurse navigation cut delays in lung cancer care, helping more patients get targeted results before first-line therapy, says Christopher D'Avella, MD.

Why Medicaid-covered kids struggle to see pediatricians: low reimbursement and practice deserts in low-income ZIP codes create real barriers to care.

Nancy L. Lewis, MD, MBS, FACP, discusses her path from the clinic to biopharma and her goals as NCCN's new CSO, including health equity and faster drug development.

Two AAD 2026 posters highlight persistent melanoma disparities: men have worse survival, whereas minority patients are less likely to receive home or hospice end-of-life care.

Study finds rural Appalachia faces soaring insomnia and sleep apnea, tied to poverty and stress, urging targeted, equity-focused sleep interventions.

Major health plans cut millions of preapproval hurdles, add 90-day continuity protections, and push real-time e-authorization to speed care access.

Despite a 24% drop since 2015, over 4 million Americans remain on long-term opioids, and they’re older, on Medicare, and increasingly coprescribed risky drugs.

Manufacturer-sponsored biologic coupons have decreased since 2018, with rising per-claim values, impacting patient costs and formulary incentives.

Social determinants of health can delay access to NGS, limiting targeted therapy use and survival outcomes in advanced cancers.

ACIP changes threaten vaccine coverage and raise costs, according to a roundtable of experts warning of widening disparities and long-term public health risks.

Ajai Chari, MD, discusses the teclistamab-daratumumab approval, highlighting durable remissions, infection management, and the need for community oncologist uptake.

From teledermatology billing to rural outreach and transplant advances, new studies and presentations reveal shifts in access, equity, and patient outcomes.

Mammography use fell significantly among younger, uninsured, and non-Hispanic White and Asian women from 2002-2022, with the 2009 USPSTF guideline change a likely driver.

Continuing conversations from last year, experts at the AAD Annual Meeting in Denver weighed the pros and cons of teledermatology and AI.

Half of working-age Medicaid enrollees face disenrollment under national work requirements, despite having greater functional impairment than those who would comply.

Joseph Mikhael, MD, has spent decades advancing the treatment of multiple myeloma, and he’s been witness to a remarkable shift in outcomes among older adults.

A new approach to posttransplant prophylaxis for graft vs host disease promises to increase access to the procedure to patients from minority groups with blood cancers. Investigators are now studying a lower dose of the treatment to limit toxicity.

Experts at the 2026 AAD Annual Meeting urged dermatologists to engage in advocacy to protect practices and patient access amid growing challenges.

April Armstrong, MD, MPH, discusses findings from the TRACE study, which evaluated the real-world effectiveness of tralokinumab in patients with skin of color with AD.